Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.61 |
| ▸ | DRD3 | P35462 | 4/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | DRD5 | P21918 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6907003 | 0.98 | DRD2 (0.62) | DRD2DRD3DRD1DRD5HTR2A | |
| SCHEMBL28263467 | 0.91 | DRD2 (0.67) | DRD2DRD3DRD1DRD5HTR2A | |
| SCHEMBL6901761 | 0.91 | DRD2 (0.56) | DRD2DRD3DRD1DRD5HTR2A | |
| SCHEMBL2641069 | 0.84 | DRD2 (0.50) | DRD2DRD3DRD1DRD5HTR2A | |
| SCHEMBL18489460 | 0.83 | DRD2 (0.50) | DRD2DRD3DRD1DRD5HTR2A | |
| Ammonia Solution, Strong SCHEMBL7667257 | 0.80 | DRD2 (0.56) | DRD2DRD3DRD1DRD5CHRM2 | |
| SCHEMBL8854649 | 0.79 | DRD2 (0.54) | DRD2DRD3DRD1DRD5HTR2A | |
| SCHEMBL7061674 | 0.79 | DRD2 (0.46) | DRD2DRD3DRD1DRD5HTR2A | |
| SCHEMBL6901862 | 0.79 | DRD1 (0.58) | DRD2DRD3DRD1DRD5HTR2A | |
| SCHEMBL14116130 | 0.78 | DRD2 (0.53) | DRD2DRD3DRD1DRD5HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| CN-101137652-A | Pyrimidine compounds having tie2 (tek) inhibitory activity | ASTRAZENECA AB (SE) | 2008-03-05 | — | — | CN | disclosed |
| EP-1863805-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006082373-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| US-6656932-B2 | Treating osteoarthritis, rheumatoid arthritis, cancer, inflammation, and heart failure | WARNER-LAMBERT COMPANY | 2003-12-02 | — | — | US | disclosed |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | MMP15, MMP13, MMP3 | DRD2 2848/4885DRD3 1626/4885DRD1 2119/4885 |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | TEK, TYMP, TIE1 | DRD2 3225/4885DRD3 3648/4885DRD1 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.